Get access

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis

  • Protocol
  • Intervention


  • M Clerico,

  • F Faggiano,

  • J Palace,

  • G Rice,

  • M Tintorè,

  • L Durelli

Dr Marinella Clerico, Resident in Neurology, Dipartimento di Neuroscienze, Università degli Studi di Torino- Ospedale S.Luigi Gonzaga, Regione Gonzole 10, Orbassano, Torino, 10043, ITALY.


This is the protocol for a review and there is no abstract. The objectives are as follows:

The primary objective of this review will be to evaluate the efficacy and safety of early treatment with GA or IFN beta on proportion of CIS patients delayed to convert to MS.

Secondary objectives will be:
1. In those patients who develop CDMS to asses the time to second relapse and the annual relapse rate.
2. To assess the effect on surrogate markers of disease activity, such as MRI occurrence of new active lesions or changes of disease burden.

Get access to the full text of this article